The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Expands bioprocessing footprint across Asia
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated
